Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: Results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

Philip J. Mease, Saima Chohan, Ferran J.Garcia Fructuoso, Michael E. Luggen, Proton Rahman, Siba P. Raychaudhuri, Richard C. Chou, Alan M. Mendelsohn, Stephen J. Rozzo, Alice Gottlieb

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: Results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds